Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population

被引:2
|
作者
Sutandhio, Silvia [1 ]
Furukawa, Koichi [1 ]
Kurahashi, Yukiya [1 ]
Marini, Maria Istiqomah [1 ]
Effendi, Gema Barlian [1 ]
Hasegawa, Natsumi [1 ]
Ishimaru, Hanako [1 ]
Nishimura, Mitsuhiro [1 ]
Arii, Jun [1 ]
Mori, Yasuko [1 ]
机构
[1] Kobe Univ, Ctr Infect Dis, Div Clin Virol, Grad Sch Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
COVID-19; Elderly; Omicron; Vaccination; Neutralizing antibody; EXPRESSION; FUSION;
D O I
10.1016/j.jiph.2023.05.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Omicron variants with immune evasion have emerged, and they continue to mutate rapidly, raising concerns about the weakening of vaccine efficacy, and the very elderly populations are vulnerable to Coronavirus Disease 2019 (COVID-19). Therefore, to investigate the effect of multiple doses of mRNA vaccine for the newly emerged variants on these populations, cross-neutralizing antibody titers were examined against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, including BQ.1.1 and XBB. Methods: Blood samples were taken from residents at four long-term care facilities in Hyogo prefecture, Japan (median age, 91 years), after 3rd (n = 67) and 4th (n = 48) mRNA vaccinations, from April to October 2022. A live virus microneutralization assay was performed to determine the neutralizing antibody titers in participants' sera.Results: After 3rd vaccination, cross-neutralizing antibody prevalence against conventional (D614G) virus, Delta, Omicron BA.2, BA.5, BA.2.75, BQ.1.1, and XBB were 100%, 97%, 81%, 51%, 67%, 4%, and 21%, respectively. After 4th vaccination, the antibody positivity rates increased to 100%, 100%, 98%, 79%, 92%, 31%, and 52%, respectively. The 4th vaccination significantly increased cross-neutralizing antibody titers against all tested variants. Conclusion: The positivity rates for BQ.1.1 and XBB increased after 4th vaccination, although the titer value was lower than those of BA.5 and BA.2.75.Considering the rapid mutation of viruses and the efficacy of vaccines, it may be necessary to create a system that can develop vaccines suitable for each epidemic in consideration of the epidemic of the virus.(c) 2023 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 50 条
  • [21] Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants
    Popovic, Marko
    MICROBIAL RISK ANALYSIS, 2023, 23
  • [22] Infection with Wild Type SARS-CoV-2 Combined with Vaccination Augments Neutralizing Antibody Levels Against Variants Including Omicron
    O'Shea, Daniel
    Schuler, Charles
    Chen, Jesse
    Troost, Jonathan
    Wong, Pamela
    Chen, Kelsea
    Peng, Westley
    Gherasim, Carmen
    Manthei, David
    Valdez, Riccardo
    Baldwin, James
    O'Shea, Kelly
    Baker, James
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB24 - AB24
  • [23] Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination
    Kurahashi, Yukiya
    Furukawa, Koichi
    Sutandhio, Silvia
    Tjan, Lidya Handayani
    Iwata, Sachiyo
    Sano, Shigeru
    Tohma, Yoshiki
    Ohkita, Hiroyuki
    Nakamura, Sachiko
    Nishimura, Mitsuhiro
    Arii, Jun
    Kiriu, Tatsunori
    Yamamoto, Masatsugu
    Nagano, Tatsuya
    Nishimura, Yoshihiro
    Mori, Yasuko
    JOURNAL OF INFECTIOUS DISEASES, 2022, : 1391 - 1395
  • [24] SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5
    Abbad, Anass
    Yellin, Temima
    Singh, Gagandeep
    Fried, Miriam
    Raskin, Ariel
    Tcheou, Johnstone
    Monahan, Brian
    Gleason, Charles
    Simon, Viviana
    Carreno, Juan Manuel
    Krammer, Florian
    CELL REPORTS MEDICINE, 2024, 5 (03)
  • [25] Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster
    Kurhade, Chaitanya
    Zou, Jing
    Xia, Hongjie
    Liu, Mingru
    Chang, Hope C.
    Ren, Ping
    Xie, Xuping
    Shi, Pei-Yong
    NATURE MEDICINE, 2023, 29 (02) : 344 - 347
  • [26] Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster
    Chaitanya Kurhade
    Jing Zou
    Hongjie Xia
    Mingru Liu
    Hope C. Chang
    Ping Ren
    Xuping Xie
    Pei‑Yong Shi
    Nature Medicine, 2023, 29 : 344 - 347
  • [27] Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1 (vol 4, pg E294, 2023)
    Mykytyn, A. Z.
    Rosu, M. E.
    Kok, A.
    LANCET MICROBE, 2023, 4 (03): : E136 - E136
  • [28] Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
    Kawashiro, Keita
    Suzuki, Rigel
    Nogimori, Takuto
    Tsujino, Shuhei
    Iwahara, Naoya
    Hirose, Takayuki
    Okada, Kazufumi
    Yamamoto, Takuya
    Fukuhara, Takasuke
    Hotta, Kiyohiko
    Shinohara, Nobuo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [29] Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination
    Takheaw, Nuchjira
    Liwsrisakun, Chalerm
    Chaiwong, Warawut
    Laopajon, Witida
    Pata, Supansa
    Inchai, Juthamas
    Duangjit, Pilaiporn
    Pothirat, Chaicharn
    Bumroongkit, Chaiwat
    Deesomchok, Athavudh
    Theerakittikul, Theerakorn
    Limsukon, Atikun
    Tajarernmuang, Pattraporn
    Niyatiwatchanchai, Nutchanok
    Trongtrakul, Konlawij
    Kasinrerk, Watchara
    DIAGNOSTICS, 2022, 12 (06)
  • [30] Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults
    Um, Jihye
    Choi, Youn Young
    Kim, Gayeon
    Kim, Min-Kyung
    Lee, Kyung-Shin
    Sung, Ho Kyung
    Kim, Byung Chul
    Lee, Yoo-Kyoung
    Jang, Hee-Chang
    Bang, Ji Hwan
    Chung, Ki-Hyun
    Oh, Myoung-Don
    Park, Jun-Sun
    Jeon, Jaehyun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (09)